

July 30, 2019



# BioXcel Therapeutics to Report Second Quarter and Half Year 2019 Financial Results and Business Update

**Conference Call scheduled to discuss results on August 6, 2019 at 8:30 AM EDT**

NEW HAVEN, Conn., July 30, 2019 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ("BTI") (Nasdaq: BTAI), today announced that the Company is scheduled to release its second quarter and half year 2019 financial results on Tuesday, August 6, 2019. BTI will also hold a conference call on Tuesday, August 6, 2019 at 8:30 AM Eastern Time to discuss the financial results and provide a business update. BTI is a clinical-stage biopharmaceutical development company that utilizes novel artificial intelligence approaches to identify and advance the next wave of medicines in neuroscience and immuno-oncology.

## **Conference Call & Webcast Details**

Tuesday, August 6, 2019, 8:30 AM Eastern Time

Domestic: 1-800-239-9838

International: 1-323-994-2093

Conference ID: 2198753

Webcast: <http://public.viavid.com/index.php?id=135552>

## **Replay**

Domestic: 1-844-512-2921

International: 1-412-317-6671

Conference ID: 2198753

\*Replay available through September 6, 2019

## **About BioXcel Therapeutics, Inc. (BTI):**

BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence approaches to identify and advance the next wave of medicines in neuroscience and immuno-oncology. BTI's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BTI's two most advanced clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neuropsychiatric disorders, and BXCL701, an orally administered systemic innate immunity activator designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer in combination with other immuno-oncology agents. For more information, please visit [www.bioxccltherapeutics.com](http://www.bioxccltherapeutics.com)

## **Contact Information:**

The Ruth Group for BTI:

Janhavi Mohite

646-536-7026

[jmohite@theruthgroup.com](mailto:jmohite@theruthgroup.com)

Source: BioXcel Therapeutics, Inc.